Indoco Remedies Intrinsic Value
Indoco Remedies intrinsic value. Indoco Remedies (INDOCO) median intrinsic value is ₹493.60 from 5 valuation models (range ₹74–₹617), vs current price ₹246.80 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit Indoco Remedies share price screener.
INDOCO Valuation Methods Summary — DCF, Graham Number & P/E
Indoco Remedies intrinsic value across 5 models vs current price ₹246.80 — upside/downside and value range per method. Compare with INDOCO DCF valuation to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹617.00 | ₹555.30 - ₹678.70 | +150.0% | Book Value/Share: ₹490.53, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹493.60 | ₹444.24 - ₹542.96 | +100.0% | Revenue/Share: ₹968.42, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹493.60 | ₹444.24 - ₹542.96 | +100.0% | EBITDA: ₹136.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹617.00 | ₹493.60 - ₹740.40 | +150.0% | CF Growth: 2.5%, Discount: 15% |
| Dividend Yield Method | dividend | ₹74.04 | ₹66.64 - ₹81.44 | -70.0% | DPS: ₹0.20, Target Yield: 2.5% |
INDOCO Intrinsic Value vs Market Price — All Valuation Models
Indoco Remedies fair value range ₹74–₹617 vs current market price ₹246.80 across 5 valuation models. Read INDOCO ex-dividend dates for the complete payout history and dividend yield track record.
INDOCO Intrinsic Value Analysis — Undervalued or Overvalued?
Indoco Remedies median intrinsic value ₹493.60, current price ₹246.80 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of INDOCO?
Based on our comprehensive analysis using 5 different valuation methods, the estimated intrinsic value of Indoco Remedies (INDOCO) is ₹493.60 (median value). With the current market price of ₹246.80, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹74.04 to ₹617.00, indicating ₹74.04 - ₹617.00.
Is INDOCO undervalued or overvalued?
Based on our multi-method analysis, Indoco Remedies (INDOCO) appears to be trading below calculated value by approximately 100.0%.
INDOCO Financial Health — Key Ratios vs Industry Benchmarks
Indoco Remedies financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.96 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | -10.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.71x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
INDOCO Cash Flow Quality — Operating & Free Cash Flow
Indoco Remedies operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹192 Cr | ₹141 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹95 Cr | ₹-75 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹157 Cr | ₹-60 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹179 Cr | ₹75 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹174 Cr | ₹114 Cr | Positive Free Cash Flow | 8/10 |